Literature DB >> 16572116

VEGF receptor 2 blockade leads to renal cyst formation in mice.

S McGrath-Morrow1, C Cho, R Molls, M Burne-Taney, M Haas, D J Hicklin, R Tuder, H Rabb.   

Abstract

Polycystic kidney disease (PKD) is associated with mutations in PKD1 and PKD2 and vascular abnormalities. The links between the epithelial and vascular defects, however, are poorly understood. Vascular endothelial growth factor (VEGF) has been shown to be critical for normal kidney development. In animal models, blockade of VEGF in the perinatal period can lead to abnormal glomerular development, impaired nephrogenesis, proteinuria, and renal failure. We hypothesized that brief blockade of VEGF signaling during early postnatal kidney development can lead to renal cyst development. On days 2 and 4 of life, CD-1 mice were treated with antibodies generated against the extracellular portion of the VEGF receptor 2 (DC101), the area of the receptor where VEGF binding occurs. Mice developed renal cysts between 2 and 3 weeks. The DC101-treated mice also had increased cell proliferation in the renal tubule epithelium. In addition, mice receiving DC101 developed abnormal glomeruli, proteinuria, and patchy cellular infiltrates. Early disruption of VEGFR-2 signaling during the perinatal period results in renal cyst formation, impaired glomerulogenesis, and inflammation. VEGF could be a key link between vascular and cystic changes in kidney cyst formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16572116     DOI: 10.1038/sj.ki.5000314

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 2.  Treatment strategies and clinical trial design in ADPKD.

Authors:  Vicente E Torres
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

3.  Angiogenin expression in human kidneys and Wilms' tumours: relationship with hypoxia and angiogenic factors.

Authors:  Pramila Ramani; Alison Headford; Emile Sowa-Avugrah; Linda P Hunt
Journal:  Int J Exp Pathol       Date:  2013-02-19       Impact factor: 1.925

Review 4.  Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

Authors:  Vicente E Torres; Alessandra Boletta; Arlene Chapman; Vincent Gattone; York Pei; Qi Qian; Darren P Wallace; Thomas Weimbs; Rudolf P Wüthrich
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

5.  Perinatal Inflammatory Biomarkers and Respiratory Disease in Preterm Infants.

Authors:  Joseph M Collaco; Sharon A McGrath-Morrow; Megan Griffiths; Raul Chavez-Valdez; Charlamaine Parkinson; Jie Zhu; Frances J Northington; Ernest M Graham; Allen D Everett
Journal:  J Pediatr       Date:  2022-04-20       Impact factor: 6.314

6.  Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety.

Authors:  Fen Tang; Michelle E LeBlanc; Weiwen Wang; Dan Liang; Ping Chen; Tsung-Han Chou; Hong Tian; Wei Li
Journal:  Angiogenesis       Date:  2019-01-14       Impact factor: 9.596

Review 7.  Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

Authors:  Chelsea C Estrada; Alejandro Maldonado; Sandeep K Mallipattu
Journal:  J Am Soc Nephrol       Date:  2019-01-14       Impact factor: 10.121

Review 8.  Cell and molecular biology of kidney development.

Authors:  Kimberly J Reidy; Norman D Rosenblum
Journal:  Semin Nephrol       Date:  2009-07       Impact factor: 5.299

Review 9.  Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Authors:  Maria V Irazabal; Vicente E Torres
Journal:  Curr Hypertens Rev       Date:  2013-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.